CARsgen Therapeutics
CARsgen Therapeutics's Overview
Carsgen Therapeutics Holdings Limited is a clinical-stage biopharmaceutical company committed to developing innovative and differentiated Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. The company has built comprehensive and proprietary CAR-T technology platforms and a robust pipeline of product candidates. Carsgen aims to become a global leader in cancer immunotherapy, leveraging its cutting-edge research, strong manufacturing capabilities, and a focus on addressing unmet medical needs in oncology.
Where is CARsgen Therapeutics's Headquarters?
HQ Function
Serves as the main hub for Carsgen's global operations, including core research and development, strategic decision-making, clinical trial management, and corporate administration.
Notable Features:
Situated within the prestigious Zhangjiang Hi-Tech Park, known as China's 'Silicon Valley' for biotech, offering access to advanced infrastructure, a collaborative ecosystem, and a rich talent pool.
Work Culture:
Carsgen fosters a science-driven, innovative, and patient-focused work environment. The culture emphasizes collaboration, scientific excellence, and a shared commitment to developing life-saving cancer therapies.
HQ Significance:
The Shanghai headquarters is crucial for driving Carsgen's pioneering R&D efforts in CAR-T therapies, managing its extensive clinical programs in China, and spearheading its expansion in the Asian biopharmaceutical landscape.
Values Reflected in HQ: The headquarters' location and facilities underscore Carsgen's commitment to innovation, scientific rigor, global collaboration, and its mission to deliver transformative treatments to cancer patients worldwide.
Location:
Carsgen Therapeutics maintains a strategic global presence with key operations centered in China and the United States. This includes multiple R&D centers, GMP-compliant manufacturing facilities, and corporate offices. This international footprint enables Carsgen to conduct global clinical trials, foster R&D collaborations with leading institutions worldwide, attract diverse talent, and strategically access major pharmaceutical markets to advance its mission of delivering innovative CAR-T therapies to cancer patients globally.
Street Address:
Building 11, No. 115, Lane 1399, Zuchongzhi Road, Zhangjiang Hi-Tech Park, Pudong New Area
City:
Shanghai
State/Province:
Shanghai
Country:
China
CARsgen Therapeutics's Global Presence
Cary, North Carolina, USA
Address: 8000 Regency Parkway, Suite 575, Cary, NC 27518, USA
To advance Carsgen's clinical pipeline in the United States, facilitate engagement with U.S. regulatory authorities, and build strategic partnerships within the prominent U.S. biotechnology and pharmaceutical industry.
Durham, North Carolina, USA
Address: 2400 Ellis Road, Durham, NC 27703, USA
To provide robust, scalable, and high-quality manufacturing capabilities for Carsgen's innovative cell therapies, supporting clinical trials and preparing for potential commercial supply in North America and other international markets.
Shanghai, China
Address: No. 33, Lane 1155, Chuan Qiao Road, Pudong New Area, Shanghai, China
To support the company's extensive clinical programs within China and ensure localized, high-quality manufacturing for its product candidates targeting the Chinese market and potentially other regions.
Buying Intent Signals for CARsgen Therapeutics
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of CARsgen Therapeutics
As of April 2025, CARsgen Therapeutics' leadership includes:
Investors of CARsgen Therapeutics
CARsgen Therapeutics has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Over the past 12 months, Carsgen Therapeutics has made strategic additions to its leadership team, particularly enhancing its quality assurance capabilities, and has experienced routine changes in its board composition. These changes reflect the company's ongoing growth and commitment to strong governance.
Departures
New Appointments:
Technology (Tech Stack) used by CARsgen Therapeutics
Discover the tools CARsgen Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
CARsgen Therapeutics Email Formats and Examples
Carsgen Therapeutics typically employs standard corporate email address formats. The most common structures likely involve combinations of an employee's first and last name, followed by the '@carsgen.com' domain. For example, 'jdoe@carsgen.com' or 'jane.doe@carsgen.com'.
[first_initial][last]@carsgen.com or [first].[last]@carsgen.com
Format
jdoe@carsgen.com
Example
75%
Success rate
News and media
PR Newswire • April 29, 2024
Carsgen Therapeutics Announces 2023 Annual Results and Business Update
Carsgen Therapeutics reported its financial results for the year ended December 31, 2023, and provided a comprehensive business update. The company highlighted significant progress across its innovative CAR-T pipeline, advancements in ongoing clinical trials for various cancer indications, and key strategic collaborations....more
GlobeNewswire • March 18, 2024
CARsgen Therapeutics to Present Updated Phase 1b Clinical Data for CT041 at the AACR Annual Meeting 2024
Carsgen Therapeutics announced its plan to present updated clinical data from the Phase 1b study of CT041, an autologous CAR-T cell product candidate targeting Claudin18.2 (CLDN18.2), at the American Association for Cancer Research (AACR) Annual Meeting 2024. The presentation focused on patients with CLDN18.2-positive solid tumors, including gastric/gastroesophageal junction cancer and pancreatic cancer....more
PR Newswire • November 2, 2023
Carsgen Therapeutics' CT041 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by U.S. FDA for Gastric/Gastroesophageal Junction Cancer
Carsgen Therapeutics announced that its lead product candidate, CT041, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA). This designation is for the treatment of adult patients with advanced gastric or gastroesophageal junction adenocarcinoma who are CLDN18.2-positive, marking a significant regulatory milestone for the therapy....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including CARsgen Therapeutics, are just a search away.